Seeking the Factors Predisposing to Local Skin Inflammatory State Development in Children with Type 1 Diabetes (T1DM) Treated with Continuous Subcutaneous Insulin Infusion (CSII)

 

 Buy Article Permissions and Reprints

Abstract

The often CSII treatment complication is local skin infection. The aim of the study was to analyze chosen factors predisposing to this complication.

Material and methods: We observed 40 children aged 1.9-15.6, suffering from diabetes for 0.1-12 and treated by CSII for 0.01-4.4 years in whom HbA1c, BMI, injection site and catheter insertion duration, catheter colonization, skin flora and Staphylococcus aureus carrier state were analyzed. The catheter cultures were prepared with Maki method. The skin and nasal vestibule swab were taken to detect local flora.

Results: In the culture of 43 catheters (Maki method) a positive growth (>10 cfu) was detected in 9 (21%), homogeny culture of coagulase-negative staphylococci in 7 and mixed culture (both S.epidermidis and S.aureus) in two cases. Skin inflammation of the injection site was observed in a total of 10 children (25%), in two of whom catheter culture was positive. A statistically significant relation between the presence of bacteria in the catheter and on the skin around the injection site was found. Among the examined parameters, the relation between the catheter colonization and HbA1c, female sex and BMI were observed.

Conclusions: Metabolic control, female sex and BMI influence the development of a skin inflammatory state in patients treated with CSII. S.aureus carrier state has no impact either on catheter colonization or the development of an infection. However, bacteria skin occurrences can predispose to catheter colonization by the strain as well as to developing an inflammation.

References

• 1 Bruttomesso D, Pianta A, Crazzolara E, scaldaferri E, Lora L, Guarneri G, Mongillo A, Gennaro R, Miola M, Moretti M, Confortin L, Beltramello GP, Pias M, aritussio A. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life.  Diabetes UK. 2002;  19 628-634
  PubMedGoogle Scholar
• 2 Campos JM, Mc Namara AM, Howard BJ. Specimen collection and processing in Clinical and Pathogenic Microbiology. Ed. Howard B et al Mosby. 1994: 213-242
  Google Scholar
• 3 Chantelau E, Lange G, Sonnenberg GE, Berger M. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment.  Diabetes Care. 1987;  10 478-482
  CrossrefPubMedGoogle Scholar
• 4 Chantelau E, Spraul M, Muhlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience.  Diabetologia. 1989;  3 421-426
  PubMedGoogle Scholar
• 5 Dudley S, Hammond PJ. Safety aspects of continuous subcutaneous insulin infusion (CSII).  Diabet Med. 2002;  19 ((suppl. 2)) A50
  CrossrefPubMedGoogle Scholar
• 6 Duncan JA, Malone JI. Continuous basal insulin infusion: an effective means to achieve good glycemic control without premeal boluses.  Diabetes Care. 1984;  7 114-117
  CrossrefPubMedGoogle Scholar
• 7 Van Faasen I, Razenberg PP, Simoons-Smit AM, Van der Veen EA. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy.  Diabetes Care. 1989;  12 153-155
  CrossrefPubMedGoogle Scholar
• 8 John SF, Hillier VF, Handley PS, Derrick MR. Adhesion of staphylococci to polyurethane and hydrogel-coated polyurethane catheters assayed by an improved radiolabelling technique.  J Med Microbiol. 1995;  43 133-140
  PubMedGoogle Scholar
• 9 Liebl A, Krinelke L. Long-term results of insulin pump therapy (CSII) in adolescents and adults with type 1 diabetes mellitus in Germany.  Diabetol Pol. 2003;  10 179-185
  PubMedGoogle Scholar
• 10 Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years.  Diabet Med. 2002;  19 746-751
  CrossrefPubMedGoogle Scholar
• 11 Mecklenberg RS, Benson EA, Benson JW, Fredlund PN, Guinn T, Metz RJ, Nielsen RL, Sannar CA. Acute complications associated with insulin infusion therapy.  JAMA. 1984;  252 3265-3269
  CrossrefPubMedGoogle Scholar
• 12 Nowakowska M, Jarosz-Chobot P, Minkina-Pędras M, Deja G, Muchacka-Bianga M, Firek-Pędras M. Does bacterial strains infect subcutaneous cannulas of the insulin pumps?.  Pediatr Diabetes. 2004;  5 ((Suppl. 1)) 38
  CrossrefPubMedGoogle Scholar
• 13 Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes.  Diabetes Care. 2003;  26 1142-1146
  PubMedGoogle Scholar
• 14 Renard E, Rostane T, Carriere C, Marchandin H, Jacques-Apostol D, Lauton D, Gibert-Boulet F, Bringer J. Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas.  Diabetes Metab. 2001;  27 62-65
  PubMedGoogle Scholar
• 15 Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.  Diabetes Care. 1999;  22 784-788
  CrossrefPubMedGoogle Scholar
• 16 Shah A, Mond J, Walsh S. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.  Antimicrob Agents Chemother. 2004;  48 2704-2707
  CrossrefPubMedGoogle Scholar
• 17 Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis.  Diabetes Care. 2003;  26 1079-1087
  CrossrefPubMedGoogle Scholar

Correspondence

P. Jarosz-Chobot

Department of Pediatrics, Endocrinology and Diabetes

Medical University of Silesia, 40-752 Katowice

Medykow 16

Poland

Phone: +48/332/07 17 16 55

Fax: +48/322/07 16 53

Email: pjarosz-chobot@slam.katowice.pl